Articles by Daniel Marsh
Wetour Robotics Soars 145% Before 1-for-100 Reverse Split; Vote on 2 Trillion Share Plan Looms
Wetour Robotics (WETO) surges 145% pre-reverse split; shareholders to vote on 2 trillion share plan and Class B stock with 100 votes per share.
Plug Power Slips as Texas Asset Sale Raises Cash Burn Questions
Plug Power shares slipped 1.9% to $2.05 as the company closed a Texas asset sale, raising concerns about its cash burn and liquidity position.
Medicare Part D Subsidy Phaseout Poses Enrollment Risks for Standalone Plans
Centene (CNC) is most exposed to Medicare Part D subsidy phaseout, with 90% of its drug plan members in standalone plans. The end of the $3.6B demo could trigger enrollment shifts.
Trump Accounts Draw $1.5B to S&P 500 ETF; Fee Impact Minimal
Trump Accounts have attracted $1.5B into SPYM ETF, generating about $300K in annual fees for State Street. The impact is minimal near-term but offers a long-term retail pipeline.
Ambarella Surges 20% on NXP Takeover Talks; Valuation Concerns Emerge
Ambarella shares soared nearly 20% after a report that NXP Semiconductors is in acquisition talks, but the premium raises valuation questions.
AT&T Stock Rebounds After $23B Spectrum Deal, Debt Concerns Loom
AT&T shares rebounded 0.7% to $23.38 after a two-day slide, following its $23B spectrum acquisition from EchoStar. The deal adds $14.5B in short-term debt, with leverage expected to peak at 3.2x.
Mangoceuticals Rockets 173% on Nuclear Merger; Existing Holders Left with 4%
Mangoceuticals (MGRX) shares soared 173.5% to $0.8029 after announcing a reverse merger with Nuclea Energy, with existing shareholders retaining only 4% pre-PIPE.
Tesla Stock Retreats as Shanghai Export Reliance Raises Investor Concerns
Tesla shares gave up early gains after Elon Musk dismissed a report about splitting China operations, but concerns over Shanghai's export dependence and margin pressures persist.
Novo Nordisk Shares Plunge 9% as ZEUS Trial Fails to Show Cardiovascular Benefit
Novo Nordisk shares fell sharply after ZEUS trial data showed no significant cardiovascular benefit, wiping out $20.5 billion in market cap and underscoring heavy reliance on GLP-1 franchise.